OpGen to Provide Business Update and Financial Results for the First Quarter 2023 on May 15th at 4:30 p.m. Eastern Time
May 08 2023 - 7:30AM
OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced
today that the Company will provide a business update and report
its first quarter 2023 financial results after the close of the
U.S. financial markets on Monday, May, 15th, 2023. OpGen’s
management team will host a live conference call and audio webcast
at 4:30 p.m. Eastern Time to discuss the Company’s financial
results and provide an update on business activities.
Conference Call Details |
U.S. Dial-in Number:International Dial-in
Number:Webcast: |
1-877-704-44531-201-389-0920https://viavid.webcasts.com/starthere.jsp?ei=1611539&tp_key=76976884dc |
|
|
Replay Details |
|
U.S. Dial-in Number:International Dial-in Number:Replay PIN: |
1-844-512-29211-412-317-667113738364 |
Following the conclusion of the conference call, a replay will
be available through May 29th, 2023. The live, listen-only webcast
of the conference call may also be accessed by visiting the
Investors section of the Company’s website at www.opgen.com. A
replay of the webcast will be available following the conclusion of
the call and will be archived on the Company’s website under
Financials & Filings.
About OpGen, Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH,
we are developing and commercializing molecular microbiology
solutions helping to guide clinicians with more rapid and
actionable information about life threatening infections to improve
patient outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the
ARES Technology Platform including ARESdb, NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction including ARESiss, ARESid, ARESasp, and AREScloud, as
well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Investor & Press Contact:Alyssa
FactorEdison Group afactor@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024